NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater